PLoS ONE (Jan 2022)

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)

  • Irini Sereti,
  • Kathryn Shaw-Saliba,
  • Lori E. Dodd,
  • Robin L. Dewar,
  • Sylvain Laverdure,
  • Shawn Brown,
  • Olivier Tshiani Mbaya,
  • Jean Jacques Muyembe Tamfum,
  • Placide Mblala-Kingebeni,
  • Ydrissa Sow,
  • Esther Akpa,
  • Mory Cherif Haidara,
  • Karine Fouth Tchos,
  • Abdoul Habib Beavogui,
  • Aaron Neal,
  • Dona Arlinda,
  • Dewi Lokida,
  • Louis Grue,
  • Mary Smolskis,
  • Laura A. McNay,
  • Dehkontee Gayedyu-Dennis,
  • Guillermo M. Ruiz-Palacios,
  • Abelardo Montenegro-Liendo,
  • Moctar Tounkara,
  • Seydou Samake,
  • Ganbolor Jargalsaikhan,
  • Delgersaikhan Zulkhuu,
  • Shera Weyers,
  • Tyler Bonnett,
  • Gail E. Potter,
  • Randy Stevens,
  • Adam Rupert,
  • Jamila Aboulhab,
  • Jean-Luc Biampata,
  • Alexandre Delamo,
  • Bienvenu Salim Camara,
  • Herman Kosasih Indonesia,
  • Muhammad Karyana,
  • James T. Duworko,
  • Justino Regalado-Pineda,
  • Paola del Carmen Guerra-de-Blas,
  • Seydou Doumbia,
  • Djeneba Dabitao,
  • Naranjargal Dashdorj,
  • Naranbaatar Dashdorj,
  • Kevin Newell,
  • Alyson Francis,
  • Kevin Rubenstein,
  • Victoria Bera,
  • Iman Gulati,
  • Ratna Sardana,
  • Monica Millard,
  • Renee Ridzon,
  • Sally Hunsberger

Journal volume & issue
Vol. 17, no. 9

Abstract

Read online

In response to the COVID-19 pandemic, COVID-19 vaccines have been developed, and the World Health Oraganization (WHO) has granted emergency use listing to multiple vaccines. Studies of vaccine immunogenicity data from implementing COVID-19 vaccines by national immunization programs in single studies spanning multiple countries and continents are limited but critically needed to answer public health questions on vaccines, such as comparing immune responses to different vaccines and among different populations.